DK0646595T3 - Nukleinsyrer-bindende oligomerer med N-forgrening til terapi og diagnostik - Google Patents

Nukleinsyrer-bindende oligomerer med N-forgrening til terapi og diagnostik

Info

Publication number
DK0646595T3
DK0646595T3 DK94113569T DK94113569T DK0646595T3 DK 0646595 T3 DK0646595 T3 DK 0646595T3 DK 94113569 T DK94113569 T DK 94113569T DK 94113569 T DK94113569 T DK 94113569T DK 0646595 T3 DK0646595 T3 DK 0646595T3
Authority
DK
Denmark
Prior art keywords
branching
nucleic acid
diagnostics
therapy
binding oligomers
Prior art date
Application number
DK94113569T
Other languages
English (en)
Inventor
Dr Antonius Loebberding
Dr Burkhard Mielke
Christoph Schwemler
Dr Eckhard Schwenner
Dr Udo Stropp
Dr Wolfgang Springer
Dr Axel Kretschmer
Dr Thorsten Poetter
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Application granted granted Critical
Publication of DK0646595T3 publication Critical patent/DK0646595T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK94113569T 1993-09-13 1994-08-31 Nukleinsyrer-bindende oligomerer med N-forgrening til terapi og diagnostik DK0646595T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4331012A DE4331012A1 (de) 1993-09-13 1993-09-13 Nukleinsäuren-bindende Oligomere mit N-Verzweigung für Therapie und Diagnostik

Publications (1)

Publication Number Publication Date
DK0646595T3 true DK0646595T3 (da) 1999-07-19

Family

ID=6497576

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94113569T DK0646595T3 (da) 1993-09-13 1994-08-31 Nukleinsyrer-bindende oligomerer med N-forgrening til terapi og diagnostik

Country Status (10)

Country Link
US (1) US5623049A (da)
EP (1) EP0646595B1 (da)
JP (1) JPH07118243A (da)
AT (1) ATE172984T1 (da)
AU (1) AU676349B2 (da)
CA (1) CA2131755A1 (da)
DE (2) DE4331012A1 (da)
DK (1) DK0646595T3 (da)
ES (1) ES2124345T3 (da)
SI (1) SI0646595T1 (da)

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223833B1 (en) * 1991-05-24 2007-05-29 Isis Pharmaceuticals, Inc. Peptide nucleic acid conjugates
US5539082A (en) * 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
DE4408534A1 (de) * 1994-03-14 1995-09-28 Hoechst Ag Substituierte N-Ethyl-Glycinderivate zur Herstellung von PNA und PNA-/DNA-Hybriden
DE4427980A1 (de) * 1994-08-08 1996-02-15 Bayer Ag Nukleinsäuren-bindende Oligomere für Therapie und Diagnostik
US6465650B1 (en) 1995-03-13 2002-10-15 Aventis Pharma Deutschland Gmbh Substituted N-ethylglycine derivatives for preparing PNA and PNA/DNA hybrids
US6077857A (en) * 1995-11-13 2000-06-20 Smithkline Beecham Corporation Hemoregulatory compounds
DE19600362C2 (de) * 1996-01-08 1998-11-12 Wolf Prof Dr Bertling Verfahren zur Erfassung und Quantifizierung von Nucleinsäure-Molekülen
US6506906B1 (en) 1996-02-26 2003-01-14 California Institute Of Technology Preparation and use of bifunctional molecules having DNA sequence binding specificity
EP1023288A1 (en) 1996-02-26 2000-08-02 California Institute Of Technology Stereochemical control of the dna binding affinity, sequence specificity, and orientation-preference of chiral hairpin polyamides in the minor groove
US6555692B1 (en) 1996-02-26 2003-04-29 California Institute Of Technology Preparation and use of bifunctional molecules having DNA sequence binding specificity
US6143901A (en) * 1996-07-31 2000-11-07 Genesoft, Inc. Complex formation between dsDNA and pyrrole imidazole polyamides
WO1998037066A1 (en) 1996-02-26 1998-08-27 California Institute Of Technology Improved polyamides for binding in the minor groove of double stranded dna
US6090947A (en) 1996-02-26 2000-07-18 California Institute Of Technology Method for the synthesis of pyrrole and imidazole carboxamides on a solid support
GB9621367D0 (en) * 1996-10-14 1996-12-04 Isis Innovation Chiral peptide nucleic acids
US6110676A (en) * 1996-12-04 2000-08-29 Boston Probes, Inc. Methods for suppressing the binding of detectable probes to non-target sequences in hybridization assays
US6962778B1 (en) 1997-09-25 2005-11-08 Boston Probes, Inc. Methods, kits and compositions for suppressing the binding of detectable probes to non-target sequences in hybridization assays
ATE478090T1 (de) 1997-10-27 2010-09-15 Boston Probes Inc SICH AUF ßPNA MOLECULAR BEACONSß BEZIEHENDE VERFAHREN, TESTSÄTZE UND ZUSAMMENSETZUNGEN
US6485901B1 (en) 1997-10-27 2002-11-26 Boston Probes, Inc. Methods, kits and compositions pertaining to linear beacons
WO1999031273A2 (en) * 1997-12-12 1999-06-24 Digene Corporation Universal collection medium
US6326479B1 (en) 1998-01-27 2001-12-04 Boston Probes, Inc. Synthetic polymers and methods, kits or compositions for modulating the solubility of same
JP4503828B2 (ja) * 1998-02-11 2010-07-14 ユニバーシティー オブ ヒューストン 光生成試薬を用いる化学反応および生化学反応のための方法および装置
US6361942B1 (en) 1998-03-24 2002-03-26 Boston Probes, Inc. Method, kits and compositions pertaining to detection complexes
US7981599B1 (en) 1998-07-31 2011-07-19 Boston Probes, Inc. Non-nucleic acid probes, probe sets, methods and kits pertaining to the detection of individual human chromosomes X, Y, 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 12, 16, 17, 18 and 20 as 13/21 as a pair
WO2000034521A1 (en) * 1998-12-08 2000-06-15 Boston Probes, Inc. Methods, kits and compositions for the identification of nucleic acids electrostatically bound to matrices
AU2001251115A1 (en) 2000-03-31 2001-10-15 Trustees Of Boston University Use of locally applied dna fragments
US7439016B1 (en) * 2000-06-15 2008-10-21 Digene Corporation Detection of nucleic acids by type-specific hybrid capture method
US7601497B2 (en) 2000-06-15 2009-10-13 Qiagen Gaithersburg, Inc. Detection of nucleic acids by target-specific hybrid capture method
EP1292606A4 (en) * 2000-06-23 2004-03-24 Yissum Res Dev Co POSITIVELY CHARGED PEPTIDIC NUCLEIC ACID ANALOGS WITH IMPROVED PROPERTIES
ATE432994T1 (de) 2000-09-26 2009-06-15 Boston Probes Inc Sonden, sondensätzen,verfahren und kits zur nachweis, identifizierung und/oder die zählung von bakterien
EP1356113B1 (en) * 2000-12-15 2012-07-18 Life Technologies Corporation Methods for determining organisms
EP1412517B1 (en) * 2001-03-09 2006-11-29 Boston Probes, Inc. Methods, kits and compositions of combination oligomers
US7211654B2 (en) * 2001-03-14 2007-05-01 Regents Of The University Of Michigan Linkers and co-coupling agents for optimization of oligonucleotide synthesis and purification on solid supports
ATE527376T1 (de) 2001-05-18 2011-10-15 Boston Probes Inc Pna-sonden, sondensätze, verfahren und kits im zusammenhang mit dem nachweis von candida
EP1432826B1 (en) 2001-09-24 2012-12-12 Life Technologies Corporation Methods, kits and compositions pertaining to the suppression of detectable probe binding to randomly distributed repeat sequences in genomic nucleic acid
US6716961B2 (en) 2001-10-30 2004-04-06 Isis Innovation Limited Chiral peptide nucleic acids with a N-aminoethyl-d-proline backbone
WO2003080857A2 (en) * 2002-03-21 2003-10-02 Boston Probes,Inc. Pna oligomers, oligomers sets, methods and kits pertaining to the detection of bacillus anthracis
US20030211509A1 (en) * 2002-03-26 2003-11-13 Wiley Steven R. TNF-delta ligand and uses thereof
US20040005611A1 (en) * 2002-05-17 2004-01-08 Hyldig-Nielsen Jens J. PNA probes, probe sets, methods and kits pertaining to the determination of Listeria
US20040137469A1 (en) * 2002-09-08 2004-07-15 Casale Ralph A Methods, compositions and libraries pertaining PNA dimer and PNA oligomer synthesis
US20040259132A1 (en) * 2002-11-22 2004-12-23 Henrik Stender Peptide nucleic acid probes for analysis of pseudomonas (sensu stricto)
CA2941594C (en) 2002-12-20 2021-07-06 Celera Corporation Genetic polymorphisms of the protein receptor c (procr) associated with myocardial infarction, methods of detection and uses thereof
CA2547072C (en) 2003-11-26 2015-06-23 Applera Corporation Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof
US7306916B2 (en) * 2004-05-04 2007-12-11 Dako Denmark A/S Methods for detecting chromosome aberrations
JP5236286B2 (ja) 2004-05-07 2013-07-17 セレラ コーポレーション 肝線維症に関連する遺伝的多型、その検出方法および使用
WO2006016978A1 (en) * 2004-06-30 2006-02-16 Applera Corporation Analog probe complexes
JP2008522588A (ja) * 2004-12-06 2008-07-03 バイオヴェリス コーポレイション 炭疽菌（Ｂａｃｉｌｌｕｓａｎｔｈｒａｃｉｓ）を検出するための方法及び組成物
US20060292586A1 (en) * 2004-12-17 2006-12-28 Schroth Gary P ID-tag complexes, arrays, and methods of use thereof
WO2006081426A2 (en) * 2005-01-28 2006-08-03 Applera Corporation Compositions and methods for terminating a sequencing reaction at a specific location in a target dna template
EP2113572B1 (en) 2005-03-11 2012-12-05 Celera Corporation Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof
JP5479731B2 (ja) 2005-06-02 2014-04-23 アドヴァンディーエックス，インコーポレイテッド 微生物を解析するためのペプチド核酸プローブ
EP1920072A2 (en) 2005-07-01 2008-05-14 Dako Denmark A/S In situ hybridization detection method
US7799530B2 (en) 2005-09-23 2010-09-21 Celera Corporation Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
DE102006039615A1 (de) * 2006-08-24 2008-03-13 Leibniz-Institut Für Pflanzenbiochemie Esterelongationsverfahren zum sequenzgesteuerten Aufbau alternierender Peptid-Peptoid-Polymere (Peptid-Peptoid-Polymere)
US7910303B2 (en) 2006-10-20 2011-03-22 Celera Corporation Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof
EP2118310B1 (en) * 2006-12-29 2013-03-06 Applied Biosystems, LLC Systems and methods for detecting nucleic acids
CN101978070A (zh) * 2006-12-29 2011-02-16 应用生物系统公司 检测核酸的系统和方法
JP2010515464A (ja) * 2007-01-11 2010-05-13 イエール・ユニバーシテイ Ｈｉｖ細胞表面受容体の標的化不活性化のための組成物および方法
EP2183386A1 (en) 2007-05-31 2010-05-12 Yale University A genetic lesion associated with cancer
EP3620465B1 (en) 2007-07-03 2025-02-19 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
US8039212B2 (en) 2007-11-05 2011-10-18 Celera Corporation Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof
US20090221620A1 (en) 2008-02-20 2009-09-03 Celera Corporation Gentic polymorphisms associated with stroke, methods of detection and uses thereof
EP2636756B2 (en) 2008-05-27 2019-11-20 Dako Denmark A/S Compositions and methods for detection of chromosomal aberrations with novel hybridization buffers
CA2726187A1 (en) 2008-05-30 2009-12-23 Yale University Targeted oligonucleotide compositions for modifying gene expression
EP3093351B1 (en) 2008-07-09 2018-04-18 Celera Corporation Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof
WO2010062546A1 (en) 2008-10-27 2010-06-03 Qiagen Gaithersburg Inc. Fast results hybrid capture assay on an automated platform
JP6108661B2 (ja) * 2009-01-28 2017-04-05 キアジェン ゲイサーズバーグ インコーポレイテッド 配列特異的な大量試料調製方法およびアッセイ法
EP2401396B1 (en) 2009-02-26 2016-11-23 Dako Denmark A/S Methods for performing a stringent wash step in hybridization applications
US8309356B2 (en) * 2009-04-01 2012-11-13 Yale University Pseudocomplementary oligonucleotides for targeted gene therapy
EP2425019B1 (en) * 2009-05-01 2014-03-19 QIAGEN Gaithersburg, Inc. A non-target amplification method for detection of rna splice-forms in a sample
AU2010265889A1 (en) 2009-06-25 2012-01-19 Yale University Single nucleotide polymorphisms in BRCA1 and cancer risk
WO2011027219A1 (en) 2009-09-04 2011-03-10 Progenika Biopharma, S.A. High throughput detection of small genomic deletions and insertions
US20120215459A1 (en) 2009-09-04 2012-08-23 Marianne Stef High throughput detection of genomic copy number variations
JP5826752B2 (ja) 2009-09-14 2015-12-02 キアジェン ゲイサーズバーグ インコーポレイテッド 細胞学用培地に固定された組織サンプルから核酸またはタンパク質を回収するための組成物および方法
US20110268810A1 (en) 2009-11-02 2011-11-03 Yale University Polymeric materials loaded with mutagenic and recombinagenic nucleic acids
US8445228B2 (en) * 2009-11-16 2013-05-21 Massachusetts Institute Of Technology Enhancement of in vitro translation by nanoparticle conjugates
US20130040294A1 (en) 2009-12-02 2013-02-14 Steen H. Matthiesen Compositions and methods for performing hybridizations with no denaturation
WO2011087789A2 (en) 2009-12-22 2011-07-21 Becton, Dickinson And Company Methods for the detection of microorganisms
CA2787924A1 (en) 2010-01-29 2011-08-04 Qiagen Gaithersburg, Inc. Methods and compositions for sequence-specific purification and multiplex analysis of nucleic acids
CA2787781A1 (en) 2010-01-29 2011-08-04 Qiagen Gaithersburg, Inc. Method of determining and confirming the presence of an hpv in a sample
EP2516681B1 (en) * 2010-02-11 2017-10-18 Nanostring Technologies, Inc Compositions and methods for the detection of preferably small rnas by bridge hybridisation and ligation
US20110269735A1 (en) 2010-04-19 2011-11-03 Celera Corporation Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof
WO2011133803A1 (en) 2010-04-21 2011-10-27 Helix Therapeutics, Inc. Compositions and methods for targeted inactivation of hiv cell surface receptors
WO2011133802A1 (en) 2010-04-21 2011-10-27 Helix Therapeutics, Inc. Compositions and methods for treatment of lysosomal storage disorders
JP2013528049A (ja) 2010-05-19 2013-07-08 キアゲン ガイサーズバーグ アイエヌシー． 核酸の配列特異的な精製及び多重分析のための方法及び組成物
JP6153866B2 (ja) 2010-05-25 2017-06-28 キアゲン ガイサーズバーグ アイエヌシー． 迅速なハイブリッド捕捉アッセイ、及び関連する戦略的に切断されたプローブ
US20120108651A1 (en) 2010-11-02 2012-05-03 Leiden University Medical Center (LUMC) Acting on Behalf of Academic Hospital Leiden (AZL) Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
CN103597095B (zh) 2011-02-24 2016-08-17 奇亚根盖瑟斯堡股份有限公司 用于检测hpv核酸的材料和方法
US9801948B2 (en) 2011-09-21 2017-10-31 Yale University Antimicrobial compositions and methods of use thereof
WO2013046033A1 (en) 2011-09-30 2013-04-04 Dako Denmark A/S Hybridization compositions and methods using formamide
EP2768974B1 (en) 2011-10-21 2017-07-19 Dako Denmark A/S Hybridization compositions and methods
WO2013082529A1 (en) 2011-12-02 2013-06-06 Yale University Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery
US10465042B2 (en) 2011-12-02 2019-11-05 Yale University Poly(amine-co-ester) nanoparticles and methods of use thereof
US9895451B2 (en) 2011-12-02 2018-02-20 Yale University Formulations for targeted release of agents to low pH tissue environments or cellular compartments and methods of use thereof
JP6375289B2 (ja) 2012-04-05 2018-08-15 マサチューセッツ インスティテュート オブ テクノロジー 免疫刺激組成物およびその使用方法
WO2014033314A1 (en) 2012-09-03 2014-03-06 Uab Bioseka Antisense oligonucleotide targeting bacterial glucosyltransferases
WO2014093291A1 (en) 2012-12-10 2014-06-19 Advandx, Inc. Use of probes for mass spectrometric identification of microorganisms or cells and associated conditions of interest
US9956294B2 (en) 2013-01-18 2018-05-01 H. Lee Moffitt Cancer Center And Research Institute, Inc. Targeted sensitization of non-del(5q) malignant cells
US9777274B2 (en) 2013-03-15 2017-10-03 Techulon Inc. Antisense molecules for treatment of staphylococcus aureus infection
SG11201507141SA (en) 2013-03-15 2015-10-29 Techulon Inc Antisense molecules for treatment of staphylococcus aureus infection
WO2014169206A2 (en) 2013-04-11 2014-10-16 Carnegie Mellon University Divalent nucleobase compounds and uses therefor
WO2014169216A2 (en) 2013-04-11 2014-10-16 Carnegie Mellon University TEMPLATE-DIRECTED γPNA SYNTHESIS AND γPNA TARGETING COMPOUNDS
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
LT6214B (lt) 2013-10-07 2015-08-25 Uab "Bioseka" Priešprasminiai oligonukleotidai aterosklerozės ir kardiovaskulinių infekcijų prevencijai
US10159652B2 (en) 2013-10-16 2018-12-25 The University Of British Columbia Device for formulating particles at small volumes
US10449254B2 (en) 2013-11-03 2019-10-22 The Regents Of The University Of California Ionic liquids for transdermal drug delivery
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
WO2015172149A1 (en) 2014-05-09 2015-11-12 Yale University Hyperbranched polyglycerol-coated particles and methods of making and using thereof
AU2015259362B2 (en) 2014-05-12 2018-02-15 The Johns Hopkins University Engineering synthetic brain penetrating gene vectors
WO2015175545A1 (en) 2014-05-12 2015-11-19 The Johns Hopkins University Highly stable biodegradable gene vector platforms for overcoming biological barriers
EP3200804A4 (en) 2014-10-01 2018-04-18 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
WO2016081621A1 (en) 2014-11-18 2016-05-26 Yale University Formulations for targeted release of agents under low ph conditions and methods of use thereof
US10682422B2 (en) 2014-11-18 2020-06-16 Yale University Formulations for targeted release of agents under low pH conditions and methods of use thereof
JP6764870B2 (ja) 2015-02-24 2020-10-07 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 連続フローマイクロ流体システム
WO2016168197A1 (en) 2015-04-15 2016-10-20 Yale University Compositions for enhancing delivery of agents across the blood brain barrier and methods of use thereof
AU2016385135B2 (en) 2016-01-06 2022-02-17 The University Of British Columbia Bifurcating mixers and methods of their use and manufacture
CA3011363A1 (en) 2016-01-12 2017-07-20 Interleukin Genetics, Inc. Methods for predicting response to treatment
US11136597B2 (en) 2016-02-16 2021-10-05 Yale University Compositions for enhancing targeted gene editing and methods of use thereof
CA3014795A1 (en) 2016-02-16 2017-08-24 Yale University Compositions and methods for treatment of cystic fibrosis
EP3420086A1 (en) 2016-02-26 2019-01-02 Yale University COMPOSITIONS AND METHODS OF USING piRNAS IN CANCER DIAGNOSTICS AND THERAPEUTICS
WO2017173453A1 (en) 2016-04-01 2017-10-05 The Brigham And Women's Hospital, Inc. Stimuli-responsive nanoparticles for biomedical applications
WO2017197128A1 (en) 2016-05-11 2017-11-16 Yale University Poly(amine-co-ester) nanoparticles and methods of use thereof
JP7179354B2 (ja) 2016-08-29 2022-11-29 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 皮膚処置のためのイオン種に基づく局所処方物
CN114907272A (zh) 2016-09-26 2022-08-16 卡耐基梅隆大学 二价核碱基化合物及其用途
WO2018064755A1 (en) 2016-10-03 2018-04-12 Precision Nanosystems Inc. Compositions for transfecting resistant cell types
WO2018112470A1 (en) 2016-12-16 2018-06-21 The Brigham And Women's Hospital, Inc. Co-delivery of nucleic acids for simultaneous suppression and expression of target genes
EP3554556B1 (en) 2016-12-19 2022-03-09 Ventana Medical Systems, Inc. Peptide nucleic acid conjugates
US10329620B2 (en) 2017-01-12 2019-06-25 Cardioforecast Ltd. Methods and kits for treating cardiovascular disease
WO2018187493A1 (en) 2017-04-04 2018-10-11 Yale University Compositions and methods for in utero delivery
US11077199B2 (en) 2017-08-09 2021-08-03 Massachusetts Institute Of Technology Albumin binding peptide conjugates and methods thereof
EP3713644B1 (en) 2017-11-20 2024-08-07 University of Georgia Research Foundation, Inc. Compositions and methods for modulating hif-2a to improve muscle generation and repair
CN111491667A (zh) 2017-12-18 2020-08-04 文塔纳医疗系统公司 肽核酸缀合物
WO2019139997A1 (en) 2018-01-09 2019-07-18 Trucode Gene Repair, Inc. Polymer-based nanoparticles, related formulation methods, and apparatus
US20210315820A1 (en) 2018-07-30 2021-10-14 Trucode Gene Repair, Inc. Lipid nanoparticle formulations comprising nucleic acid mimics
US11939593B2 (en) 2018-08-01 2024-03-26 University Of Georgia Research Foundation, Inc. Compositions and methods for improving embryo development
WO2020033951A1 (en) 2018-08-10 2020-02-13 Yale University Compositions and methods for embryonic gene editing in vitro
JP7570107B2 (ja) 2018-08-31 2024-10-21 イェール ユニバーシティー ドナーオリゴヌクレオチドベースの遺伝子編集を亢進するための組成物および方法
SG11202101984PA (en) 2018-08-31 2021-03-30 Univ Yale Compositions and methods for enhancing triplex and nuclease-based gene editing
WO2020112195A1 (en) 2018-11-30 2020-06-04 Yale University Compositions, technologies and methods of using plerixafor to enhance gene editing
US11814464B2 (en) 2019-04-29 2023-11-14 Yale University Poly(amine-co-ester) polymers and polyplexes with modified end groups and methods of use thereof
US20220249660A1 (en) 2019-06-06 2022-08-11 Sitokine Limited Compositions and methods for treating lung, colorectal and breast cancer
US20220243211A1 (en) 2019-06-21 2022-08-04 Yale University Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof
US20220372474A1 (en) 2019-06-21 2022-11-24 Yale University Hydroxymethyl-modified gamma-pna compositions and methods of use thereof
US12496357B2 (en) 2019-07-31 2025-12-16 Yale University Compositions and methods for treating sickle cell disease
WO2021028469A1 (en) 2019-08-12 2021-02-18 Sitokine Limited Compositions and methods for treating cytokine release syndrome and neurotoxicity
AU2020336992A1 (en) 2019-08-30 2022-04-14 Yale University Compositions and methods for delivery of nucleic acids to cells
WO2021205013A1 (en) 2020-04-09 2021-10-14 Sitokine Limited Compositions and methods for treating covid-19
EP4168471A1 (en) 2020-06-19 2023-04-26 Yale University Poly(amine-co-ester) polymers with modified end groups and enhanced pulmonary delivery
CA3193424A1 (en) 2020-08-31 2022-03-03 Yale University Compositions and methods for delivery of nucleic acids to cells
US20250154317A1 (en) 2022-02-18 2025-05-15 Yale University Branched poly(amine-co-ester) polymers for more efficient nucleic expression
WO2024081736A2 (en) 2022-10-11 2024-04-18 Yale University Compositions and methods of using cell-penetrating antibodies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3022967B2 (ja) * 1985-03-15 2000-03-21 アンチバイラルズ インコーポレイテッド 立体規則性ポリヌクレオチド結合ポリマー
US4994368A (en) * 1987-07-23 1991-02-19 Syntex (U.S.A.) Inc. Amplification method for polynucleotide assays
US5175266A (en) * 1991-04-19 1992-12-29 Triplex Pharmaceutical Corporation Nucleosides and oligonucleosides with a phosphate-free internucleoside backbone and process for preparing the same
DK51092D0 (da) * 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
WO1993004701A1 (en) * 1991-09-05 1993-03-18 University Of Connecticut Targeted delivery of poly- or oligonucleotides to cells
MX9207334A (es) * 1991-12-18 1993-08-01 Glaxo Inc Acidos nucleicos peptidicos y formulacion farma- ceutica que los contiene
DE4331011A1 (de) * 1993-09-13 1995-03-16 Bayer Ag Nukleinsäuren-bindende Oligomere mit C-Verzweigung für Therapie und Diagnostik

Also Published As

Publication number Publication date
EP0646595B1 (de) 1998-11-04
ATE172984T1 (de) 1998-11-15
SI0646595T1 (en) 1999-02-28
US5623049A (en) 1997-04-22
EP0646595A1 (de) 1995-04-05
DE4331012A1 (de) 1995-03-16
DE59407223D1 (de) 1998-12-10
AU676349B2 (en) 1997-03-06
AU7154394A (en) 1995-03-23
JPH07118243A (ja) 1995-05-09
ES2124345T3 (es) 1999-02-01
CA2131755A1 (en) 1995-03-14

Similar Documents

Publication Publication Date Title
DK0646595T3 (da) Nukleinsyrer-bindende oligomerer med N-forgrening til terapi og diagnostik
DK0646596T3 (da) Nucleinsyre-bindende oligomerer med C-forgrening til terapi og diagnostik
DE58909463D1 (de) Neue kondensierte heterocyclische Verbindungen und ihre Verwendung für Heilmittel.
DK1398379T3 (da) Forbindelser og fremgangsmåder til immunterapi og diagnose af tuberkulose
ATE241014T2 (de) Hiv-2 varianten
ATE315643T1 (de) Cdn apoptosis modulierende proteine, sie kodierende dns und verfahren zu ihrer verwendung
EP1003782A4 (en) HERPES SIMPLEX VIRUS ACCESS MEDIATOR LIGAND AND METHODS OF USE
DK0509398T3 (da) Quinoxaliner, fremgangsmåder til deres fremstilling samt deres anvendelse
BR0014663A (pt) Moléculas de ácido nucléico para a detecção de bactérias e unidades filogenéticas de bactérias
NO304598B1 (no) Forgrenet-amino-substituerte tiazoler, anvendelse av dem og farmas°ytiske blandinger inneholdende dem
DE69629674D1 (de) Dns-sequenzen des humanen cytomegaloviruses
TR199801039T2 (xx) Yeni fenilamidin t�revlerinin elde edilmesine y�nelik usul.
WO1987000751A3 (en) Use of oxirancarboxylic acids for the treatment of hyperlipemia
DK1005532T3 (da) Isolerede nukleinsyremolekyler kodende for SSX familiemedlemmer og anvendelser deraf
DK0870036T3 (da) Syntetisk pattedyrs-alfa-N-acetylglucosaminidase og genetiske sekvenser kodende derfor
ES2165358T3 (es) Utilizaciones de la proteinquinasa de neurofilamento/tau pk40.
DE69421665D1 (de) Anomere Fluorribosylamine
ATE113598T1 (de) Substituierte vinylcephalosporine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
DK0612763T3 (da) Cykliske angiopeptinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
FI963055A0 (fi) Kondensaatio- ja additiopolymeereja, jotka sisältävät N,N'-sillan sisältäviä bis(tetrametyylipiperidinyylioksi)-ryhmiä
DK0688786T3 (da) Hydrazino- og hydroxyamino-14beta-hydroxyandrostanderivater med aktivitet på det cardiovaskulære system, fremgangsmåder til deres fremstilling og farmaceutiske præparater indeholdende disse.
NO963901D0 (no) Fremgangsmåte for nukleinsyrediagnostisering under anvendelse av riboprober, RNase-fordöyelse og molekylvektutelukkelseskromatografi
FR2721617B1 (fr) Fragments d'acides nucléiques, dérivés du génome de Mycobacterium xenopi et leurs applications.
ITRM920224A0 (it) Sistema ottico per la combinazione di due cammini ottici, in particolare i cammini ottici di uno strumento di diagnostica oculare e di un altro strumento.
ITAQ930006A0 (it) Idrogeli morbidi o semirigidi per uso biomedico.